Atezolizumab: all 521 studies that test it

Page 5 of 6. Open to participants first (107), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
• A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04028050Phase 3
• Neoadjuvant Atezolizumab in Cutaneous MelanomaActive, not recruitingNCT04020809Phase 1
• Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)Active, not recruitingNCT04017455Phase 2
• Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCStatus unknownNCT03991403Phase 3
• Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel ChemotherapyActive, not recruitingNCT03977194Phase 3
• Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)CompletedNCT03976518Phase 2
• Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant GliomaWithdrawnNCT03973879Phase 1/2
• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabWithdrawnNCT03973333Phase 1/2
• Durvalumab and Olaparib in Metastatic or Recurrent Endometrial CancerStatus unknownNCT03951415Phase 2
• Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)CompletedNCT03946358Phase 2
• A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03922997Phase 3
• Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast CancerTerminatedNCT03894007Phase 2
• Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell LymphomaTerminatedNCT03892525Phase 1
• A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal AdenocarcinomaTerminatedNCT03866239Phase 1
• Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic CancerStatus unknownNCT03835949Phase 1
• Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and NeckCompletedNCT03818061Phase 2
• Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerCompletedNCT03802604Early Phase 1
• Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerCompletedNCT03801304Phase 2
• Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer PatientsActive, not recruitingNCT03799835Phase 3
• A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural MesotheliomaWithdrawnNCT03786419Phase 2
• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerActive, not recruitingNCT03775265Phase 3
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
• FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer PatientsCompletedNCT03721653Phase 2
• Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT03708224Phase 2
• Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical CystectomyActive, not recruitingNCT03697850Phase 2
• A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerCompletedNCT03695380Phase 1
• A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell CarcinomaWithdrawnNCT03693573Phase 3
• PEnile Cancer Radio- and Immunotherapy CLinical Exploration StudyCompletedNCT03686332Phase 2
• A Trial of Ipatasertib in Combination With AtezolizumabActive, not recruitingNCT03673787Phase 1/2
• Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsStatus unknownNCT03647956Phase 2
• Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLCTerminatedNCT03644823Phase 2
• Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder CancerStatus unknownNCT03620435Phase 2
• This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated CancersTerminatedNCT03618953Phase 1
• SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical CancerActive, not recruitingNCT03614949Phase 2
• Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint AtezolizumabCompletedNCT03612791Phase 2
• Atezolizumab Trial in Endometrial Cancer - AtTEndCompletedNCT03603184Phase 3
• Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian CancerCompletedNCT03598270Phase 3
• Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerActive, not recruitingNCT03595592Phase 3
• Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the CervixCompletedNCT03556839Phase 3
• Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung CancerActive, not recruitingNCT03540420Phase 2
• An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT03533283Phase 1/2
• Phase II Study of Atezolizumab + Bevacizumab in Endometrial CancerActive, not recruitingNCT03526432Phase 2
• A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal CarcinomaCompletedNCT03519295Phase 2
• Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and CarboplatinWithdrawnNCT03498222Phase 1
• Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast CancerCompletedNCT03464942Phase 2
• The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCLActive, not recruitingNCT03463057Phase 2
• Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)Active, not recruitingNCT03448835Phase 2
• Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung CancerCompletedNCT03438318Phase 1
• Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose TherapyTerminatedNCT03422523Phase 2
• Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune ResponsivenessActive, not recruitingNCT03421288Phase 2
• BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
• Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial CancerCompletedNCT03359239Phase 1
• PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03357224Phase 2
• Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian CancerCompletedNCT03353831Phase 3
• Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerActive, not recruitingNCT03340376Phase 2
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaActive, not recruitingNCT03321643Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerTerminatedNCT03292172Phase 1
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboActive, not recruitingNCT03281954Phase 3
• Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasCompletedNCT03276468Phase 2
• Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLCStatus unknownNCT03262454Phase 2
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
• Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based ChemotherapyTerminatedNCT03208712Early Phase 1
• Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial CarcinomaActive, not recruitingNCT03179943Phase 2
• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
• Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
• Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast CancerCompletedNCT03164993Phase 2
• NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
• A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Active, not recruitingNCT03148418Phase 3
• AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast CancerTerminatedNCT03147040Phase 2
• Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal CancerCompletedNCT03127007Phase 1/2
• Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast CancerActive, not recruitingNCT03125928Phase 2
• A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerCompletedNCT03101280Phase 1
• A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder CancerCompletedNCT03093922Phase 2
• PDL-1 Targeting in Resectable Oesophageal CancerCompletedNCT03087864Phase 2
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 2
• Immunotherapy as Second-line in Patient With Small Cell Lung CancerCompletedNCT03059667Phase 2
• Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT StudyActive, not recruitingNCT02997228Phase 3
• Atezolizumab as Induction Therapy in Non-small Cell Lung CancerCompletedNCT02994576Phase 2
• A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerActive, not recruitingNCT02989584Phase 1/2
• Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal CancerTerminatedNCT02982694Phase 2
• Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedActive, not recruitingNCT02935361Phase 1/2
• Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902029Phase 2
• A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)CompletedNCT02892318Phase 1
• ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+BevacizumabCompletedNCT02891824Phase 3
• ACTolog in Patients With Solid CancersCompletedNCT02876510Phase 1
• Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other TumorsCompletedNCT02876224Phase 1
• Atezolizumab in Treating Patients With Cancer Following Adoptive Cell TransferActive, not recruitingNCT02862275Phase 1
• Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerActive, not recruitingNCT02849496Phase 2
• Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeActive, not recruitingNCT02846623Phase 2
• Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway InhibitorCompletedNCT02814669Phase 1
• A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCompletedNCT02813785Phase 3
• Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic TumorsCompletedNCT02794571Phase 1
• Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic MyelomaTerminatedNCT02784483Phase 1
• LOAd703 Oncolytic Virus Therapy for Pancreatic CancerCompletedNCT02705196Phase 1/2
• Preoperative MPDL3280A in Transitional Cell Carcinoma of the BladderCompletedNCT02662309Phase 2
• Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian CancerCompletedNCT02659384Phase 2
• Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCompletedNCT02655822Phase 1
• A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid TumorsCompletedNCT02650713Phase 1

← Atezolizumab overview